文献速递脑血管病外科神经重症

替奥普罗宁治疗动脉瘤性蛛网膜下腔出血的II期随机对照试验

A phase II randomized controlled trial of tiopronin for aneurysmal subarachnoid hemorrhage.
PubMed 文献 · J Neurosurg · 2019-07-12

这项前瞻性、随机、双盲、安慰剂对照、多中心II期临床试验纳入60例aSAH患者,按1:1分配接受替奥普罗宁或安慰剂,在发病96小时内开始每日3g治疗,主要疗效终点为aSAH后7±1天脑脊液3-AP水平。结果显示两组脑脊液3-AP水平无差异(11±12 nmol/mL vs 13±18 nmol/mL;p=0.766),但因数据缺失导致检验效能受限,无法确定或否定替奥普罗宁对脑脊液3-AP水平的影响。

要点

  • aSAH后7±1天脑脊液3-AP水平两组无差异(11±12 vs 13±18 nmol/mL;p=0.766)
  • 数据缺失影响检验效能,无法确定或否定替奥普罗宁对脑脊液3-AP的效果
  • 作者建议在将3-AP作为未来临床试验分子靶点前,先行观察性研究评估其作为DCI生物标志物的作用

核心结论

  • 因数据缺失影响研究检验效能,作者无法确定或否定替奥普罗宁对脑脊液3-AP水平的影响。
  • 作者认为在将3-AP作为未来临床试验的分子靶点之前,可能需要进一步开展观察性研究评估其作为DCI生物标志物的作用。

研究设计与样本

  • 前瞻性、随机、双盲、安慰剂对照、多中心II期临床试验,纳入60例aSAH患者,按1:1比例分配接受替奥普罗宁或安慰剂。
  • 治疗在aSAH发病后96小时内开始,剂量为每日3g,持续至aSAH后14天或出院(以较早者为准)。
  • 主要疗效终点为aSAH后7±1天脑脊液3-AP水平。

主要发现

  • 60例入组患者中,替奥普罗宁组29例(97%)和安慰剂组27例(93%)接受了超过一剂研究药物或安慰剂。
  • aSAH后7±1天,替奥普罗宁组41%(n=12/29)和安慰剂组48%(n=13/27)的患者有可用的脑脊液样本。
  • aSAH后7±1天两组脑脊液3-AP水平无差异(11±12 nmol/mL vs 13±18 nmol/mL;p=0.766)。
  • 预设不良事件导致替奥普罗宁组4例和安慰剂组2例提前终止治疗。

局限性

  • 研究检验效能受到数据缺失的影响。
  • aSAH后7±1天脑脊液样本仅在替奥普罗宁组41%(n=12/29)和安慰剂组48%(n=13/27)的患者中可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Delayed cerebral ischemia (DCI) is a significant contributor to poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). The neurotoxin 3-aminopropanal (3-AP) is upregulated in cerebral ischemia. This phase II clinical trial evaluated the efficacy of tiopronin in reducing CSF 3-AP levels in patients with aSAH. METHODS: In this prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial, 60 patients were assigned to receive tiopronin or placebo in a 1:1 ratio. Treatment was commenced within 96 hours after aSAH onset, administered at a dose of 3 g daily, and continued until 14 days after aSAH or hospital discharge, whichever occurred earlier. The primary efficacy outcome was the CSF 3-AP level at 7 ± 1 days after aSAH. RESULTS: Of the 60 enrolled patients, 29 (97%) and 27 (93%) in the tiopronin and placebo arms, respectively, received more than one dose of the study drug or placebo. At post-aSAH day 7 ± 1, CSF samples were available in 41% (n = 12/29) and 48% (n = 13/27) of patients in the tiopronin and placebo arms, respectively. No difference in CSF 3-AP levels at post-aSAH day 7 ± 1 was observed between the study arms (11 ± 12 nmol/mL vs 13 ± 18 nmol/mL; p = 0.766). Prespecified adverse events led to early treatment cessation for 4 patients in the tiopronin arm and 2 in the placebo arm. CONCLUSIONS: The power of this study was affected by missing data. Therefore, the authors could not establish or refute an effect of tiopronin on CSF 3-AP levels. Additional observational studies investigating the role of 3-AP as a biomarker for DCI may be warranted prior to its use as a molecular target in future clinical trials.Clinical trial registration no.: NCT01095731 (ClinicalTrials.gov).

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Ironside N, Christophe B, Bruce S, et al. A phase II randomized controlled trial of tiopronin for aneurysmal subarachnoid hemorrhage. J Neurosurg. 2019. PMID: 31299655. doi:10.3171/2019.4.JNS19478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。